410 related articles for article (PubMed ID: 15492133)
1. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
2. B1 kinin receptor does not contribute to vascular tone or tissue plasminogen activator release in the peripheral circulation of patients with heart failure.
Cruden NL; Tse GH; Fox KA; Ludlam CA; Megson I; Newby DE
Arterioscler Thromb Vasc Biol; 2005 Apr; 25(4):772-7. PubMed ID: 15681300
[TBL] [Abstract][Full Text] [Related]
3. Vascular B1 kinin receptors in patients with congestive heart failure.
Lang NN; Cruden NL; Tse GH; Bloomfield P; Ludlam CA; Fox KA; Newby DE
J Cardiovasc Pharmacol; 2008 Nov; 52(5):438-44. PubMed ID: 19033823
[TBL] [Abstract][Full Text] [Related]
4. Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Favrat B; Burnier M; Nussberger J; Lecomte JM; Brouard R; Waeber B; Brunner HR
J Hypertens; 1995 Jul; 13(7):797-804. PubMed ID: 7594444
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition.
Labinjoh C; Newby DE; Pellegrini MP; Johnston NR; Boon NA; Webb DJ
J Am Coll Cardiol; 2001 Nov; 38(5):1402-8. PubMed ID: 11691515
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Ferro CJ; Spratt JC; Haynes WG; Webb DJ
Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376
[TBL] [Abstract][Full Text] [Related]
7. Marked impairment of protease-activated receptor type 1-mediated vasodilation and fibrinolysis in cigarette smokers: smoking, thrombin, and vascular responses in vivo.
Lang NN; Gudmundsdóttir IJ; Boon NA; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2008 Jul; 52(1):33-9. PubMed ID: 18582632
[TBL] [Abstract][Full Text] [Related]
8. Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb.
Cruden NL; Lang NN; MacGillivray TJ; Uren NG; Fox KA; Newby DE
Heart Vessels; 2012 Mar; 27(2):179-85. PubMed ID: 21394642
[TBL] [Abstract][Full Text] [Related]
9. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
[TBL] [Abstract][Full Text] [Related]
10. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Cruden NL; Witherow FN; Webb DJ; Fox KA; Newby DE
Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
[TBL] [Abstract][Full Text] [Related]
11. Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
Witherow FN; Helmy A; Webb DJ; Fox KA; Newby DE
Circulation; 2001 Oct; 104(18):2177-81. PubMed ID: 11684627
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
13. Endothelial angiotensin-converting enzyme and neutral endopeptidase in isolated human umbilical vein: an effective bradykinin inactivation pathway.
Nowak W; Errasti AE; Armesto AR; Santín Velazque NL; Rothlin RP
Eur J Pharmacol; 2011 Sep; 667(1-3):271-7. PubMed ID: 21651905
[TBL] [Abstract][Full Text] [Related]
14. Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.
Zhang X; Recchia FA; Bernstein R; Xu X; Nasjletti A; Hintze TH
J Pharmacol Exp Ther; 1999 Feb; 288(2):742-51. PubMed ID: 9918584
[TBL] [Abstract][Full Text] [Related]
15. Marked bradykinin-induced tissue plasminogen activator release in patients with heart failure maintained on long-term angiotensin-converting enzyme inhibitor therapy.
Witherow FN; Dawson P; Ludlam CA; Fox KA; Newby DE
J Am Coll Cardiol; 2002 Sep; 40(5):961-6. PubMed ID: 12225723
[TBL] [Abstract][Full Text] [Related]
16. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of the renal responses to bradykinin by inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in anesthetized dogs.
Seymour AA; Sheldon JH; Smith PL; Asaad M; Rogers WL
J Pharmacol Exp Ther; 1994 Apr; 269(1):263-70. PubMed ID: 8169834
[TBL] [Abstract][Full Text] [Related]
18. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
[TBL] [Abstract][Full Text] [Related]
19. Interaction between neutral endopeptidase and angiotensin converting enzyme inhibition in rats with myocardial infarction: effects on cardiac hypertrophy and angiotensin and bradykinin peptide levels.
Duncan AM; James GM; Anastasopoulos F; Kladis A; Briscoe TA; Campbell DJ
J Pharmacol Exp Ther; 1999 Apr; 289(1):295-303. PubMed ID: 10087017
[TBL] [Abstract][Full Text] [Related]
20. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients.
Taddei S; Virdis A; Ghiadoni L; Mattei P; Salvetti A
J Hypertens; 1998 Apr; 16(4):447-56. PubMed ID: 9797190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
